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It is speculated that a once-daily dosage of immunosuppression can increase adherence and thereby graft survival. Until now,
there have been no studies on once-daily use of Tacrolimus extended-release formulation (TAC-ER) in children following
pediatric kidney transplantation. In 11 stable pediatric kidney recipients >10 years, eﬃcacy, safety, and tolerability of a switch
to TAC-ER were observed over one year. Adherence was determined by use of the BAASIS-Scale Interview and comparison of
individual variability of Tacrolimus trough levels. Over the observation period, two acute rejections were observed in one girl
with nonadherence and repeated Tacrolimus trough levels of 0ng/m. Beside this, there were no acute rejections in this trial. TAC
dose was increased in 3/11 patients and decreased in 2/11 patients within the course of the study. Six patients did not require
a dose adjustment. All but one patient had a maximum of 1 dose change during therapy. Mean Tacrolimus dose, trough levels,
and Glomerular ﬁltration rates were also stable. Adherence, as measured by BAASIS-Scale Interview and coeﬃcient of variation
of Tacrolimus trough levels, was good at all times. It is concluded that conversion to Tac-ER is safe in low-risk children following
pediatric kidney transplantation.
1.Introduction
Patient nonadherence to immunosuppressive therapy after
kidney transplantation is an important factor contributing
to acute rejection and decreased graft survival [1–5]. This is
especially true for adolescents [1] who are at the highest risk
of nonadherence. Fennell et al. indicated that approximately
50% of children with chronic diseases are nonadherent
[6]. It has been shown that, following pediatric renal
transplantation, nonadherence is one of the most important
contributing factors for graft rejection and loss [7]. In renal
transplantation in adults one study concluded that there
was a statistically signiﬁcant correlation between a once-
daily dose of immunosuppression and better adherence [2].
However, until now, there has been no evidence that TAC-
ER improves adherence to the immunosuppressive regimen.
In other meta-analyses there is only limited evidence that
once-daily dosing of a drug improves adherence to the
immunosuppressive regimen in other chronic diseases [8, 9].
A once-daily dose of Tacrolimus extended-release formula-
tion (TAC-ER) was safe and eﬀective in a small cohort of
children after liver transplantation [10]. No such data exists
for children after kidney transplantation.
2. Patients andMethods
2.1. Study Design. This was an open-label, controlled pros-
pective trial to determine the safety and eﬃcacy of the use
of one daily TAC-ER dose in children after kidney transplan-
tation and to improve adherence. The study was performed
in accordance with the ethics committee of Hannover Med-
ical School. It was classiﬁed as a “noninvasive prospective
trial” by the ethics committee according to German law
that does not require registration. Therefore, ICH-GCP
guidelineswerefollowedpartiallyasrequired:seriousadverse
events and adverse events were documented, but no external
monitoring was implemented. Informed consent was given
by parents and children. The study was conducted as an
investigator initiated trial. Sponsor of the study was the
Medical School of Hannover, Germany.
As this was the ﬁrst trial with TAC-ER in children after
kidney transplantation, a selected low-risk study group was2 International Journal of Nephrology
chosen:children>10yearswithaminimumofoneyearsince
kidney transplantation and with stable renal function were
eligible for the study. No acute rejections occurred within
the year before the study. Immunosuppression consisted of
either Cyclosporine A (CsA) and Mycophenolate Mofetil
(MMF) ± Prednisolone or Tacrolimus (TAC), MMF ± Pred-
nisolone.Afterconversionallparticipantswerecontinuedon
MMF twice daily in addition to Tac-ER and Prednisolone
once daily. The patients were studied from January 2008 to
January 2009. Observation time was one year.
The study was a conversion study. At study initiation
the dose of TAC-ER was calculated as the prior daily dose
of Tacrolimus. In cases of CsA therapy, daily TAC-ER dose
was calculated as follows: 6mg/m2 body surface area. Target
Tacrolimus trough level was 5–7μg/L. All patients were seen
in the outpatient clinic one week after the conversion and
then every 4 weeks for the rest of the study period. No
surveillance biopsies were performed. Indication biopsies
were mandatory in cases of increased creatinine of 15% over
baseline.
In all patients the Basel assessment of adherence to
immunosuppressive medication scale (BAASIS Scale) was
done by interview at study initiation and one year later. The
BAASIS Scale is a combination of the Siegal questionnaire
[11] and the self-report on adherence of Walsh et al. [12].
The assessment was completed with the patients, not their
parents.
The incidence of biopsy-conﬁrmed acute rejection epi-
sodes,patientandgraftsurvivalratewasassessedthroughout
the study. Safety was assessed based on individual adverse
events and the results of routine clinical laboratory tests and
assessment of vital signs.
2.2. Patients. Twelve children (age > 10 years) were eligible
for the study. One family refused consent to the study
because of the stable situation of their child. Eleven children,
mean age 14 ± 2y e a r s ,4f e m a l e ,7m a l e ,w e r ei n c l u d e di n
the study. Complete demographics are given in Table 1.T e n
patients were treated with TAC, MMF ± Prednisolone before
study start and one with CsA, MMF, and Prednisolone.
2.3. Statistics. Primary endpoint of the study was an
improvement of adherence as demonstrated by an increase
of mean percentage of self-estimated compliance after Walsh
et al. [12]. Sample size was calculated as follows: estimated
mean percentage of adherence before switch 85%, after
switch 95%, sample size 10 patients, standard deviation 7%,
and α error 5%. Statistical Power was calculated as 93.9%.
In order to calculate the intraindividual variability of
TAC trough levels, the last 5 trough levels before the
switch and before the end of the ﬁrst year after the switch
measured every 4 weeks were used to calculate the individual
coeﬃcients of variation (CV = standard deviation/mean).
Five outpatient trough levels with an interval of 4 weeks were
used. No values were excluded. Based on these values, the
mean coeﬃcient of variation was calculated for both assess-
ments. Values between diﬀerent assessments were compared
by paired t-test and those between patients by unpaired t-
test. P<. 05 was deﬁned as statistically signiﬁcant.
Table 1: Patient demographics.
Gender Male 7, female 5
Mean age 14 ± 2 years
CsA/MMF: n = 1
Immunosuppressant before
switch TAC/MMF: n = 10
pANCA-positive vasculitis: n = 2
Renal dysplasia: n = 5
Underlying disease Nephronophthisis: n = 2
Obstructive uropathy: n = 1
Congenital nephrotic syndrome:
n = 1
Living donation/cadaveric
donation 4/7
Mean time from
transplantation to switch 4.4 ± 2.6 years
Adverse events and serious adverse events were docu-
mented according to clinical practice guidelines.
3. Results
3.1. Tacrolimus Drug Exposure. Mean daily TAC dose was
4.8±2.2mg/m2 before the switch and 5.1±2.4mg/m2 (P =
n.s.) one year later. Mean trough levels were 6.2 ± 2.0ng/mL
before the switch and 6.5 ± 0.9ng/mL one year later. TAC
dose was increased in 3/11 patients and decreased in 2/11
patients within the course of the study. Six patients did
not require a dose adjustment. All but one patient had a
maximum of 1 dose change during therapy. The adjunctive
immunosuppressive therapies were not changed during the
study.
3.2. Kidney Function. The mean GFR (abbreviated Schwartz
2009 formula [13]) was 56 ± 11mL/min/1.73m2 at time of
switchand55 ±11mL/min/1.73m2 oneyearlater(P = n.s.).
There was no graft loss or patient death.
3.3. Acute Rejection. Indication biopsies due to an increase
in s-creatinine were only performed in one 16-year-old girl.
Both biopsies showed acute rejection, BANFF Grade Ia. In
both, TAC levels were 0ng/mL, and the patient reported not
having taken TAC-ER due to psychosocial problems. Both
acuterejection episodes weresensitive tosteroid pulses. After
multiple intervention by the psychosocial team, adherence
increased and TAC levels were stable.
3.4. Intraindividual Variability of Tacrolimus Levels. The
mean coeﬃcient of variation of TAC trough levels was
0.27±0.11 before the switch and 0.30 ± 0.19 one year later
(P = n.s.).
3.5.BAASISScale. TheresultsoftheBAASIS-ScaleInterview
were comparable at both times of evaluation. Results of the
important items are given in Table 2.International Journal of Nephrology 3
Table 2: Results of The BAASIS-Scale Interview concerning adherence in all patients before the switch to TAC-ER and one year later.
Before switch to TAC-ER One year after switch P
Immunosuppression not taken 3/20: once monthly 3/20: once monthly n.s.
Immunosuppression taken 2 hrs before or after prescribed time
3/20: once monthly 2/20: once monthly n.s.
2/20: once every 2 weeks 1/20: once every 2 weeks
Dose of Immunosuppression changed without advice 0/20 0/20 n.s.
Mean percentage of self-estimated compliance after Walsh et al. [12] 94 ± 7% 93 ± 7% n.s.
3.6. Serious Adverse Events. Two hospital admissions for
2 indication kidney biopsies in one 16-year-old girl and
one admission in a 17-year-old boy due to gastroenteritis
requiring i.v. rehydration took place. No other serious
adverse events were documented during the study period.
4. Discussion
This data concludes that, in a selected cohort of pediatric
kidney recipients, a switch from the standard formulation
TAC to TAC-ER is safe. The acute rejection episodes taking
place in one patient were due to nonadherence and interac-
tion problems within her family. Despite this nonadherence,
mean GFR remained stable, intraindividual variability of
trough level was low, and TAC-ER was not discontinued
in any patient. One dose adjustment of TAC-ER had to be
performed in 45% of the patients.
In adults receiving antihypertensive medication, it has
been shown that adherence can be increased from 59% to
83% when changing from a thrice-daily dose to a once-daily
doseofmedication[14].Theseﬁndingshavebeenconﬁrmed
by Weng et al. [2] who used electronically measured adher-
ence to immunosuppressive therapy. Wolﬀ et al. studied
the issue of medication adherence in 85 children with end-
stage renal disease and found that, in 4% of the patients,
nonadherence had been the primary reason for referral to
psychosocialservices[1].Theyconcludedthatnonadherence
is almost inevitable, often based on valid personal reasons.
It has been shown that adherence and education inﬂuence
the nephrologists’ recommendation for transplantation [15].
In a meta-analysis, Dobbels et al. calculated a mean nonad-
herence rate of 35.2% in children after renal transplantation.
They stated that adherence-enhancing interventions should
consist of educational strategies, behavioural strategies, and
strategies to increase social support [16]. Rianthavorn and
Ettenger [7] described diﬀerent methods of documenting
medication nonadherence and stated standard deviation
calculation for trough levels of TAC, as described by others
[17], to be highly correlated with outcomes that suggested
nonadherence, such as biopsy proven rejection. In this study
the coeﬃcient of variation of TAC trough levels was low
even before study initiation and did not change thereafter in
comparison to other immunosuppressive studies [18]. The
girl who did not take her medication in the middle of the
study period did not inﬂuence the low mean coeﬃcient of
variation, because for calculation purposes it was deﬁned
before study start that only trough levels before the switch
andinthelastmonthsofthestudyperiodwereused.Inthese
two periods, TAC trough levels were stable in this girl.
The primary endpoint, showing superiority for adher-
ence after switch to once-daily dosing, was not achieved
within our study. The “good adherence” at the beginning
of the study might explain why there was no more increase
in adherence after the switch to TAC-ER. Obviously, there
was a selection bias of adherent children in the study, only
including children without acute rejection one year before
the switch. However, this bias was accepted when designing
the study, as stable patients for the ﬁrst change to a new
immunosuppressant was a requirement. In this study only
children >10 years were included, because major diﬀerences
in pharmacokinetics can be expected in children below this
age.
Another aspect for the failure of this study to achieve
more adherence may have been the combination of TAC-ER
with MMF, which has to be administered twice daily. Future
studies with TAC-ER in children should include teenagers
with a history of nonadherence and also children <10
years. In a future study with a more high-risk population,
careful pharmacokinetic monitoring should be mandatory.
The possible positive eﬀect of TAC-ER on adherence could
be enhanced by immunosuppressive combinations needing
only once-daily application for all agents. However, possible
combinationssuchasTAC-ERandSirolimusorTAC-ERand
Azathioprine have not shown promising results in children
until now and should not therefore be used in future studies.
In studies in adults, it could be demonstrated that the
pharmacokinetic proﬁle of TAC-ER is diﬀerent compared to
TAC. In several adults TAC-ER dose has to be increased after
switch from TAC to TAC-ER to obtain the same exposure
to Tacrolimus [19]. In this small pediatric cohort, dose had
to be increased in 3/11 children. However, administration of
TAC-ER in conversion studies in adults was also safe for the
patients [20, 21].
It is concluded that TAC-ER can safely be used in a
selected low-risk cohort of pediatric kidney graft recipients
>10 years. In this selected study population, adherence could
not be improved by once-daily administration of TAC.
Abbreviations
GFR: Glomerular ﬁltration rate
TAC: Tacrolimus4 International Journal of Nephrology
TAC-ER: Tacrolimus extended-release
MMF: Mycophenolate Mofetil
CsA: Cyclosporine A
mTOR: Mammalian target of rapamycin.
Acknowledgment
ThestudywassupportedbyanunrestrictedgrantbyAstellas,
Germany.
References
[1] G. Wolﬀ,K .S t r e c k e r ,U .V e s t e r ,K .L a t t a ,a n dJ .H .H .E h r i c h ,
“Non-compliance following renal transplantation in children
and adolescents,” Pediatric Nephrology, vol. 12, no. 9, pp. 703–
708, 1998.
[2] F. L. Weng, A. K. Israni, M. M. Joﬀe et al., “Race and electroni-
cally measured adherence to immunosuppressive medications
after deceased donor renal transplantation,” Journal of the
American Society of Nephrology, vol. 16, no. 6, pp. 1839–1848,
2005.
[3] B. R. Siegal and S. M. Greenstein, “Postrenal transplant
compliance from the perspective of African- Americans,
hispanic-americans, and anglo-americans,” Advances in Renal
Replacement Therapy, vol. 4, no. 1, pp. 46–54, 1997.
[4] L.B.Hilbrands,A.J.Hoitsma,andR.A.P.Koene,“Medication
compliance after renal transplantation,” Transplantation, vol.
60, no. 9, pp. 914–920, 1995.
[ 5 ]I .S k e t r i s ,N .W a i t e ,K .G r o b l e r ,M .W e s t ,a n dS .G e r u s ,
“Factors aﬀecting compliance with cyclosporine in adult renal
transplant patients,” Transplantation Proceedings, vol. 26, no.
5, pp. 2538–2541, 1994.
[6] R. S. Fennell, L. M. Foulkes, and S. R. Boggs, “Family-
based program to promote medication compliance in renal
transplant children,” Transplantation Proceedings, vol. 26, no.
1, pp. 102–103, 1994.
[7] P. Rianthavorn and R. B. Ettenger, “Medication non-
adherence in the adolescent renal transplant recipient: a
clinician’s viewpoint,” Pediatric Transplantation, vol. 9, no. 3,
pp. 398–407, 2005.
[8] S. Kripalani, X. Yao, and R. B. Haynes, “Interventions to
enhance medication adherence in chronic medical conditions:
asystematicreview,”ArchivesofInternalMedicine,vol.167,no.
6, pp. 540–550, 2007.
[9] S. D. Saini, P. Schoenfeld, K. Kaulback, and M. C. Dubinsky,
“Eﬀect of medication dosing frequency on adherence in
chronic diseases,” The American Journal of Managed Care, vol.
15, no. 6, pp. e22–e33, 2009.
[10] T. G. Heﬀron, M. D. Pescovitz, S. Florman et al., “Once-
daily tacrolimus extended-release formulation: 1-Year post-
conversion in stable pediatric liver transplant recipients,”
American Journal of Transplantation, vol. 7, no. 6, pp. 1609–
1615, 2007.
[11] B. R. Siegal, “Postrenal transplant compliance: report of
519 responses to a self-report questionnaire,” Transplantation
Proceedings, vol. 25, no. 4, p. 2502, 1993.
[12] J. C. Walsh, S. Mandalia, and B. G. Gazzard, “Responses to
a 1 month self-report on adherence to antiretroviral therapy
are consistent with electronic data and virological treatment
outcome,” AIDS, vol. 16, no. 2, pp. 269–277, 2002.
[13] G. J. Schwartz, A. Mu˜ noz, M. F. Schneider et al., “New
equations to estimate GFR in children with CKD,” Journal of
the American Society of Nephrology, vol. 20, no. 3, pp. 629–637,
2009.
[14] S. A. Eisen, D. K. Miller, R. S. Woodward, . Spitznagel, and T.
R. Przybeck, “The eﬀect of prescribed daily dose frequency on
patient medication compliance,” Archives of Internal Medicine,
vol. 150, no. 9, pp. 1881–1884, 1990.
[15] S. L. Furth, W. Hwang, A. M. Neu, B. A. Fivush, and N.
R. Powe, “Eﬀects of patient compliance, parental education
andraceonnephrologists’recommendationsforkidneytrans-
plantation in children,” American Journal of Transplantation,
vol. 3, no. 1, pp. 28–34, 2003.
[16] F. Dobbels, R. Van Damme-Lombaert, J. Vanhaecke, and S. De
Geest, “Growing pains: non-adherence with the immunosup-
pressive regimen in adolescent transplant recipients,” Pediatric
Transplantation, vol. 9, no. 3, pp. 381–390, 2005.
[17] E. Shemesh, B. L. Shneider, J. K. Savitzky et al., “Medication
adherence in pediatric and adolescent liver transplant recipi-
ents,” Pediatrics, vol. 113, no. 4 I, pp. 825–832, 2004.
[18] L. Pape, J. H. H. Ehrich, and G. Oﬀner, “Advantages of
cyclosporin A using 2-h levels in pediatric kidney transplanta-
tion,”PediatricNephrology,vol.19,no.9,pp.1035–1038,2004.
[19] M. Crespo, M. Mir, M. Marin et al., “De novo kidney trans-
plant recipients need higher doses of Advagraf compared with
Prograf to get therapeutic levels,” Transplantation Proceedings,
vol. 41, no. 6, pp. 2115–2117, 2009.
[20] M. R. First, “First clinical experience with the new once-daily
formulation of tacrolimus,” Therapeutic Drug Monitoring, vol.
30, no. 2, pp. 159–166, 2008.
[21] R. Alloway, S. Steinberg, K. Khalil et al., “Two years post-
conversion from a prograf-based regimen to a once-daily
tacrolimus extended-release formulation in stable kidney
transplant recipients,” Transplantation, vol. 83, no. 12, pp.
1648–1651, 2007.